PRPO News and Press, Precipio Inc. From 08/15/22

Precipio, Inc. (PRPO) Q2 2022 Earnings Conference Call August 15, 2022, 17:00 ET Company Participants Ilan Danieli - Founder, President, CEO & Director Conference Call Participants Presentation Operator Welcome to the Precipio Shareholder ...

NEW HAVEN, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , welcomes Toni-Ann Mills as the Company’s Senior Director for Learning & Development. With a ~$0.5B market potential for HemeScreen, Precipio is...

NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2022 shareholder update call on Monday, August 15 th at 5:00 PM ET. The call will include updates on the Company’s curre...

Applied DNA Sciences ( APDN ) +116% . Poseida Therapeutics ( PSTX ) +81% . Ping Identity Holding ( PING ) +60% Non-GAAP EPS of -$0.34 misses by $0.22, revenue of $72.03M misses by $1.27M. Alnylam Pharmaceuticals ( ALNY ) +47% as Phase 3 tr...

Precipio ( NASDAQ: PRPO ) has entered into an agreement with Fisher Healthcare , a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers. The Fisher Healthcare channel will enable Precipio to expand access to laboratories ac...

NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that it has entered into an agreement with Fisher Healthcare , a part of Thermo Fisher Scientific to distribute its proprietary He...

NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ:PRPO ), announced today that the Company’s 2022 Annual Meeting of Stockholders was adjourned due to the fact that the percentage of stockholders participating in ...

NEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO) , today announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and mark...

NEW HAVEN, Conn., May 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO) , today announced that it has received CE-IVD approval for sale of its HemeScreen® reagents in the European Union. The approval was provided by the ...

NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announced today that American Oncology Network (AON) of Fort Myers, Florida, has completed its validation of Precipio’s proprietary IV-Cell ...